Overview Drug-drug Interaction (DDI) Rifabutin Status: Completed Trial end date: 2014-07-24 Target enrollment: Participant gender: Summary The purpose of this study is to provide dosing recommendations for the coadministration of BMS-663068 and Rifabutin with and without Ritonavir in upcoming Phase 3 studies and for prescribing information purposes Phase: Phase 1 Details Lead Sponsor: Bristol-Myers SquibbViiV HealthcareCollaborator: GlaxoSmithKlineTreatments: FostemsavirRifabutinRitonavir